During the Goldman Sachs 47th Annual Global Healthcare Conference held on June 8, 2026, in Miami, Pfizer Inc.'s CEO Albert Bourla discussed the company's strong performance and strategic direction. Bourla noted that Pfizer has consistently surpassed revenue and earnings per share (EPS) expectations in 2024, 2025, and the first quarter of 2026. This success is attributed to significant changes made to the company's commercial model in the aftermath of the COVID-19 pandemic. He emphasized the importance of 'consistency in delivery' and highlighted the role of artificial intelligence (AI) in facilitating cost reductions while enhancing operational effectiveness. Bourla expressed satisfaction with the ongoing execution of their strategy, which has allowed Pfizer to adapt and thrive in a changing healthcare landscape. The conference, which Bourla has traditionally opened, serves as a platform for discussing key developments in the healthcare sector and Pfizer's position within it.